Rivastigmine Patch
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Mild to Moderate Alzheimer's Disease
Conditions
Mild to Moderate Alzheimer's Disease
Trial Timeline
May 9, 2016 → May 7, 2018
NCT ID
NCT02703636About Rivastigmine Patch
Rivastigmine Patch is a approved stage product being developed by Novartis for Mild to Moderate Alzheimer's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02703636. Target conditions include Mild to Moderate Alzheimer's Disease.
What happened to similar drugs?
7 of 16 similar drugs in Mild to Moderate Alzheimer's Disease were approved
Approved (7) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02703636 | Approved | Completed |
| NCT01380288 | Pre-clinical | Completed |
| NCT00835159 | Approved | Completed |
Competing Products
20 competing products in Mild to Moderate Alzheimer's Disease